Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 238
Gene Symbol: ALK
ALK
0.080 GeneticVariation phenotype BEFREE One patient had an ALK G1202R mutation in a post-alectinib/pre-brigatinib biopsy, and had progressive disease as the best overall response to brigatinib. 29935304 2018
Entrez Id: 238
Gene Symbol: ALK
ALK
0.080 Biomarker phenotype BEFREE <b>Objectives:</b> To study whether ongoing clinical benefits of continuing anaplastic lymphoma kinase <i>(ALK)</i> and c-ros oncogene 1 (<i>ROS1</i>) inhibition are achieved by crizotinib treatment post progressive disease (PD) in advanced non-small cell lung cancer (NSCLC) patients harboring <i>ALK</i>/<i>ROS1</i> mutations. 29805713 2018
Entrez Id: 238
Gene Symbol: ALK
ALK
0.080 Biomarker phenotype BEFREE Four ALK positive patients with progressive disease following crizotinib treatment were identified with paired pre- and post-crizotinib tumor tissue from our previously published cohort. 29300322 2018
Entrez Id: 238
Gene Symbol: ALK
ALK
0.080 Biomarker phenotype BEFREE The appropriate therapy for patients with progressive disease following two ALK inhibitors is not well defined. 28534251 2017
Entrez Id: 238
Gene Symbol: ALK
ALK
0.080 Biomarker phenotype BEFREE Although most patients with ALK-positive non-small-cell lung cancer (NSCLC) who benefit from treatment with crizotinib ultimately develop progressive disease (PD), continuing crizotinb beyond the initial PD (CBPD) in these patients may be beneficial. 28427213 2017
Entrez Id: 238
Gene Symbol: ALK
ALK
0.080 Biomarker phenotype BEFREE In advanced ALK positive NSCLC PET was able to detect progressive disease earlier than with CT in nearly half of the assessments while both imaging tests performed similar in the others. 27137772 2016
Entrez Id: 238
Gene Symbol: ALK
ALK
0.080 AlteredExpression phenotype BEFREE Two tumors with high phospho-ALK levels and low phospho-EGFR levels achieved stable and progressive disease, respectively. 24443522 2014
Entrez Id: 238
Gene Symbol: ALK
ALK
0.080 Biomarker phenotype BEFREE All but one patient had no ground-glass opacity (GGO) lesions, indicating that most ALK-positive tumors showed a solid growth pattern without GGO on CT. Twenty were evaluable for response to chemotherapy; 10 (50.0%) had a partial response (PR), nine (45.0%) had stable disease (SD), and one (5.0%) had progressive disease (PD) with first-line chemotherapy. 24403104 2014